187 related articles for article (PubMed ID: 29477894)
21. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
22. Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression.
Pupyshev AB; Korolenko TA; Akopyan AA; Amstislavskaya TG; Tikhonova MA
Neurosci Lett; 2018 Apr; 672():140-144. PubMed ID: 29203207
[TBL] [Abstract][Full Text] [Related]
23. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
[TBL] [Abstract][Full Text] [Related]
24. Models of α-synuclein aggregation in Parkinson's disease.
Giráldez-Pérez R; Antolín-Vallespín M; Muñoz M; Sánchez-Capelo A
Acta Neuropathol Commun; 2014 Dec; 2():176. PubMed ID: 25497491
[TBL] [Abstract][Full Text] [Related]
25. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
26. α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion.
Yamakado H; Moriwaki Y; Yamasaki N; Miyakawa T; Kurisu J; Uemura K; Inoue H; Takahashi M; Takahashi R
Neurosci Res; 2012 Jun; 73(2):173-7. PubMed ID: 22475625
[TBL] [Abstract][Full Text] [Related]
27. Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice.
Roshanbin S; Aniszewska A; Gumucio A; Masliah E; Erlandsson A; Bergström J; Ingelsson M; Ekmark-Lewén S
Neurobiol Aging; 2021 May; 101():207-220. PubMed ID: 33639338
[TBL] [Abstract][Full Text] [Related]
28. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
29. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
30. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
[TBL] [Abstract][Full Text] [Related]
31. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
Febbraro F; Sahin G; Farran A; Soares S; Jensen PH; Kirik D; Romero-Ramos M
Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
[TBL] [Abstract][Full Text] [Related]
32. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Fleming SM; Salcedo J; Hutson CB; Rockenstein E; Masliah E; Levine MS; Chesselet MF
Neuroscience; 2006 Nov; 142(4):1245-53. PubMed ID: 16934409
[TBL] [Abstract][Full Text] [Related]
33. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
34. Alpha-synuclein-based models of Parkinson's disease.
Dehay B; Fernagut PO
Rev Neurol (Paris); 2016; 172(6-7):371-8. PubMed ID: 27158042
[TBL] [Abstract][Full Text] [Related]
35. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies.
Refolo V; Bez F; Polissidis A; Kuzdas-Wood D; Sturm E; Kamaratou M; Poewe W; Stefanis L; Angela Cenci M; Romero-Ramos M; Wenning GK; Stefanova N
Acta Neuropathol Commun; 2018 Jan; 6(1):2. PubMed ID: 29298733
[TBL] [Abstract][Full Text] [Related]
36. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
Gorbatyuk OS; Li S; Sullivan LF; Chen W; Kondrikova G; Manfredsson FP; Mandel RJ; Muzyczka N
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):763-8. PubMed ID: 18178617
[TBL] [Abstract][Full Text] [Related]
37. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
[TBL] [Abstract][Full Text] [Related]
38. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
39. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
[TBL] [Abstract][Full Text] [Related]
40. Behavioral Deficits and Brain α-Synuclein and Phosphorylated Serine-129 α-Synuclein in Male and Female Mice Overexpressing Human α-Synuclein.
Gabrielyan L; Liang H; Minalyan A; Hatami A; John V; Wang L
J Alzheimers Dis; 2021; 79(2):875-893. PubMed ID: 33361597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
